Breaking Down Chemring Group PLC Financial Health: Key Insights for Investors

Investors scanning Chemring Group PLC's latest results will find a mix of steady top-line progress and strategic investment: revenue rose by 2% to £497.5m (or 2.8% on a constant currency basis), underpinned by a surge in the Countermeasures & Energetics division where order intake jumped 20% to £602m while Sensors & Information saw order intake climb 19.3% to £179m, helping drive a record order book of £1.345bn (with £431m earmarked for recognition in 2026); profitability showed momentum too, with underlying operating profit at £74.3m and an underlying margin of 14.8% (EPS 19.7p), even as net debt rose to £93.3m (net debt/underlying EBITDA 0.90x) to fund capacity expansion expected to add £100m pa by 2028, supported by a refinanced £180m RCF and up to £275m in liquidity facilities; cash generation remained robust - underlying operating cash inflow £32.0m (80% of underlying EBITDA) and a two‑year cash conversion of 99% - metrics that inform a market cap around £1.01bn and an analyst consensus price target of £583, while risks include higher leverage, FX exposure and the USD 9m disposal of the explosive hazard detection business amid ambitions to reach £1bn revenue by 2030.

Chemring Group PLC (CHG.L) - Revenue Analysis

• Reported revenue: £497.5 million, up 2.0% year‑on‑year.
• Constant currency revenue growth: 2.8%, reflecting FX headwinds versus reported sterling results.
• Record order book: £1,345 million, providing multi‑year visibility.
• Revenue expected to be recognized from order book in 2026: £431 million.

• The 2% reported revenue increase masks a stronger underlying performance once FX is stripped out (2.8% constant currency).
• Countermeasures & Energetics was the primary growth engine-20% higher order intake to £602m-indicating sustained defence demand and backlog conversion potential.
• Sensors & Information delivered a 19.3% uplift in order intake to £179m, helping offset a weaker near‑term revenue run‑rate caused by short‑term delays in UK government expenditure.
• With £431m of the £1.345bn order book expected to be recognised as revenue in 2026, revenue visibility is high for the coming year.

Chemring Group PLC (CHG.L) - Profitability Metrics

Chemring Group PLC reported continued margin expansion and earnings growth driven by higher volumes in Countermeasures & Energetics and disciplined commercial execution.

• Underlying operating profit: £74.3m, up 6.8% (underlying operating margin 14.8% vs 14.3% in 2024).
• Statutory operating profit: £73.4m, up 29.7% (reflecting strong operational execution and higher volumes).
• Underlying EPS: 19.7p, up 4.2% (improved shareholder value).
• Effective tax rate on underlying PBT: 20.9% (up from 18.5% in 2024, aligned with UK corporation tax rate).
• Net debt: £93.3m (increase from £75.3m in 2024 due to capacity expansion investments).
• Working capital as % of revenue: 14.8% (improved from 18.1% in 2024 due to commercial contracting and tighter working capital management).

Key drivers and investor implications:

• Margin uplift reflects better mix and higher Countermeasures & Energetics volumes supporting both underlying and statutory profits.
• EPS growth of 4.2% shows incremental shareholder value despite higher tax rates and investment-related debt increases.
• Net debt rise to £93.3m is targeted to expand capacity - a strategic investment that may pressure leverage metrics near term but supports future revenue growth.
• Working capital reduction to 14.8% of revenue improves cash conversion and reduces funding strain, partially offsetting higher net debt.

For related ownership and investor behavior context see: Exploring Chemring Group PLC Investor Profile: Who's Buying and Why?

Chemring Group PLC (CHG.L) - Debt vs. Equity Structure

• Net debt (31 Oct 2025): £93.3 million (up from £75.3 million at 31 Oct 2024)
• Net debt / underlying EBITDA: 0.90x - a conservative leverage position
• Revolving credit facility (RCF): increased from £150 million to £180 million, facilities available until December 2028
• Additional liquidity facilities available: up to £275 million
• Ordinary shares with voting rights: 272,349,319
• Cumulative preference shares (no voting rights): 62,500
• Net debt increase primarily due to capital expenditure on capacity expansion to meet growing market demand

• Capital structure implications:
  • Debt profile: increased but within conservative bounds (0.90x net debt / EBITDA).
  • Liquidity: RCF uplift and broader facilities support near-term funding for projects and M&A optionality.
  • Equity base: established ordinary share count provides shareholder continuity; small preference share issuance has limited governance impact.
• Strategic context:
  • Net debt purposely rose to finance capacity expansion to capture growing market demand.
  • Available facilities (£180m RCF and up to £275m liquidity) reduce refinancing risk and permit staged investment.

Chemring Group PLC (CHG.L) - Liquidity and Solvency

Chemring's near-term liquidity and solvency profile is characterized by strong cash generation, disciplined working capital management and targeted use of leverage to fund capacity expansion.

• Underlying operating cash inflow: £32.0m (80% of underlying EBITDA)
• Two‑year rolling cash conversion: 99%
• Working capital: 14.8% of revenue (down from 18.1% in 2024)
• Statutory operating profit for the year: £24.9m (reported vs £37.4m in 2024)
• Net debt: £93.3m (up from £75.3m in 2024) - primarily driven by capacity expansion investments
• Committed facilities: £180m revolving credit facility plus additional liquidity facilities up to £275m

Key implications for investors:

• High cash conversion (99% two‑year rolling) and £32.0m operating cash inflow indicate resilient cash generation supporting operations and investment.
• Working capital reduction to 14.8% of revenue improves free cash flow potential and reduces short‑term funding needs.
• Net debt increase to £93.3m is attributable to strategic capacity expansion; leverage should be viewed alongside EBITDA and cash conversion metrics.
• Liquidity is underpinned by a £180m RCF and additional facilities up to £275m, providing headroom for execution and cyclical resilience.

For deeper investor context on ownership and market positioning, see: Exploring Chemring Group PLC Investor Profile: Who's Buying and Why?

Chemring Group PLC (CHG.L) - Valuation Analysis

• Analyst consensus: 'Buy' with a price target of £583.00, implying upside from the current share price.
• Net debt increased to £93.3m from £75.3m in 2024, which raises leverage and may compress valuation multiples until earnings absorb the additional debt.
• Working capital intensity reduced to 14.8% of revenue from 18.1% in 2024, improving cash conversion and operational efficiency.
• Record order book of £1.345bn provides strong forward revenue visibility, supporting higher forward multiples.
• Strategic investments and capacity expansion are expected to drive future earnings growth, which could lift valuation if execution meets targets.

Chemring Group PLC (CHG.L) Risk Factors

Chemring Group PLC faces several material risks that investors should weigh alongside growth opportunities. The key exposures span leverage, operational timing, currency volatility, project execution, portfolio changes and customer concentration in government contracts.

• Rising leverage: net debt increased to £93.3 million from £75.3 million in 2024, elevating financial leverage and future interest obligations.
• Operational timing risk: short-term delays in UK government spending have impacted the Sensors & Information division, creating revenue timing pressure.
• Currency exposure: recent weakness in the US dollar and Australian dollar versus sterling can compress reported revenue and margins when translated to GBP.
• Capital expenditure and execution risk: significant capex for capacity expansion (including projects in Norway) introduces potential cost overruns, commissioning delays and lower-than-expected near-term returns.
• Portfolio adjustment: disposal of the explosive hazard detection business for USD 9.0 million in cash reduces revenue diversification and alters future recurring revenue composition.
• Customer concentration: heavy reliance on government contracts exposes the company to policy changes, defence and security budget reallocations, and procurement timing shifts.

Risk mitigation and monitoring priorities for investors include:

• Debt servicing and covenant monitoring given higher net debt levels.
• Close tracking of capex schedules and contingency plans for Norway and other expansion projects.
• Hedging and reporting of FX sensitivity due to exposure to USD and AUD receipts.
• Assessment of revenue mix post-disposal and the impact on recurring cash flows.
• Monitoring government budget cycles and contract pipelines that drive Sensors & Information and defence-related revenues.

Further context on shareholder composition and investor interest can be found here: Exploring Chemring Group PLC Investor Profile: Who's Buying and Why?

Chemring Group PLC (CHG.L) - Growth Opportunities

• Record order book: £1.345 billion, providing a multi-year revenue pipeline.
• 2026 revenue visibility: £431 million expected to be recognized as revenue in 2026 from the order book.
• 2028 target uplift: Capacity expansion (notably in Norway) expected to add ~£100 million of revenue per annum from 2028.
• Net debt evolution: Net debt increased to £93.3 million from £75.3 million in 2024, reflecting strategic investments to meet demand.
• Long-term revenue goal: Management aims for annual revenue of £1 billion by 2030, aligned with growing NATO and global defense spend.
• Portfolio focus: Disposal of the explosive hazard detection business to sharpen focus on core competencies and higher-return segments.

• Commercial contracting focus: more disciplined contract terms and pricing are improving margin predictability.
• Working capital: reductions as a percentage of revenue are freeing cash to fund expansion without proportionate equity issuance.
• Return expectations: Norway capacity is expected to generate attractive returns tied to stable defense procurement cycles.